Aspirin angina therapy

Unstable angina/Non-Q-wave Ml - The recommended dose is 120 units/kg of body weight (but not more than 10,000 units) subcutaneously every 12 hours with concurrent oral aspirin (75 to 165 mg/day) therapy. Concurrent aspirin therapy is recommended except when contraindicated. Continue treatment until the patient is clinically stabilized. The usual duration of treatment is 5 to 8 days. 

Drug therapy of acute coronary syndromes including unstable angina and non-Q-wave myocardial infarction includes use of aspirin, heparin and anti-ischaemic drugs and is similar in older patients to other age groups. Activation of platelet thromboxane production in the coronary circulation has been demonstrated in unstable angina. The risk of myocardial infarction or death is reduced by approximately 50% by early aspirin therapy in recommended doses of 160-325 mg per day and continued... 

Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek 1 et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994 89(l) 81-8. 

Prevention of ischemic complications of unstable angina and non-Q-wave MI (with oral aspirin therapy) Subcutaneous lmg/kgql2h. 

Mehta SR, Yusuf S, Peters RJ, et al, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention the PCI-CURE study. Lancet 2001 358 527-533. 

Unstable angina although the therapy of choice for unstable angina rests on the use of beta-blockers and aspirin, calcium antagonists may add further value due to their spasmolytic effects. 

Antiplatelet therapy (aspirin or clopidogrel) reduces the incidence of fatal and of nonfatal myocardial infarction in patients with unstable angina, used alone or with low-dose heparin. 

Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, Gore JM, Thompson BW, Toiler GH, Kleiman NS, Cannon C, Braunwald E. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol 1997 79(4) 391-6. 

---